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Waist‑height ratio and waist are 
the best estimators of visceral fat 
in type 1 diabetes
Erika B. Parente1,2,3,4,7, Stefan Mutter1,3,4,7, Valma Harjutsalo1,3,4,5, Aila J. Ahola1,3,4, 
Carol Forsblom1,3,4 & Per‑Henrik Groop1,3,4,6*
Visceral fat is associated with cardiovascular and kidney disease. However, the relationship between 
body composition and anthropometric measures in type 1 diabetes is unknown. Using z‑statistics, 
we ranked the ability of body mass index (BMI), waist circumference (WC), waist‑hip ratio (WHR), 
waist‑height ratio (WHtR) and a body shape index (ABSI) to capture measures of body composition 
from 603 Dual‑energy‑X‑Ray‑Absorptiometry scans of adults with type 1 diabetes. Albuminuria was 
defined as urinary albumin excretion rate of at least 30 mg/24 h. Women with albuminuria had higher 
visceral fat mass % (VFM%) (0.9 vs. 0.5%, p = 0.0017) and lower appendicular lean mass % (AppLM%) 
(25.4 vs 26.4%, p = 0.03) than those without. Men with albuminuria had higher VFM% (1.5 vs. 1.0%, 
p = 0.0013) and lower AppLM% (30.0 vs 32.3, p < 0.0001) than those without. In men, WHtR estimated 
VFM% best (z‑statistics = 21.1), followed by WC (z = 19.6), BMI (z = 15.1), WHR (z = 14.6) and ABSI 
(z = 10.1). In women, the ranking was WC (z = 28.9), WHtR (z = 27.3), BMI (z = 20.5), WHR (z = 12.7) and 
ABSI (z = 10.5). Overall, the ranking was independent of albuminuria. Adults with type 1 diabetes and 
albuminuria have greater VFM% and lower AppLM% than those without. WHtR and WC best estimate 
the VFM% in this population, independently of albuminuria and sex.
Abbreviations
AFM  Android fat mass
AFM%  AFM/total body weight × 100
AppLM  Appendicular-lean-mass (both legs and arms lean mass)
AppLM%  AppLM/total body-weight × 100
BFM  Body fat mass
BFM%  BFM/total body weight × 100
BLM  Body lean mass
BLM%  BLM/total body weight × 100
BMI  Body mass index
DN  Diabetic nephropathy
DXA  Dual-energy X-ray Absorptiometry
HDL  High-density lipoprotein cholesterol
VFM  Visceral fat mass
VFM%  VFM/total body weight × 100
WC  Waist circumference
WHR  Waist-hip-ratio
WHtR  Waist-height ratio
The obesity epidemic is spreading worldwide. Along with this global trend, also people with type 1 diabetes 
have exhibited weight gain over the last  years1. Such an increase in body weight will most likely have a harmful 
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impact on the cardiovascular mortality rate of this  population2,3. Previous research from our group showed 
that the mortality rate of individuals with type 1 diabetes increases starting from a body mass index (BMI) of 
24.8 kg/m2, which is still within the normal  range1. Therefore, it brings up the question of whether the BMI cut-
off to define central obesity and cardiovascular risk in individuals with type 1 diabetes should be lower than the 
traditionally used 30 kg/m2.
BMI is the most commonly used tool to classify obesity, although it is an inadequate biomarker of abdomi-
nal  obesity4. It does not differentiate muscle from fat nor give the precise information regarding the amount 
of body fat mass, which better defines  obesity5 and which is positively associated with cardiovascular disease 
(CVD)6,7. Furthermore, BMI neither distinguishes women from men concerning their body fat nor provides 
any information about the fat distribution, which is relevant for the risk of  CVD8. Given that obesity is causally 
related to diabetic nephropathy (DN) in individuals with type 1  diabetes9, it would be of utmost importance to 
understand how the anthropometric measures are related to their body composition and especially visceral fat, 
which has been associated with dyslipidemia, insulin resistance,  CVD8,10, and chronic kidney  disease11,12 in the 
general population.
The Dual-energy X-ray Absorptiometry (DXA) is a well-recognized method to study fat distribution and 
body  composition5. Unfortunately, the high cost hinders its use in routine clinical practice. On the other side, 
anthropometric measures such as waist circumference (WC) and waist-hip ratio (WHR) are accessible and of 
low cost, although they have certain  limitations13. Another practical anthropometric measure is the waist-height 
ratio (WHtR) that has been associated with CVD in the general population and has the advantage to have a uni-
sex cut-off value of 0.513–16, moreover, a meta-analysis has shown that WHtR is a better screening tool than WC 
and BMI for adult cardiometabolic risk  factors16. A body shape index (ABSI) is another formula in which WC 
is adjusted for weight and height and has been a predictor of mortality, independently of BMI, in an American 
population from the National Health and Nutrition Examination Survey (NHANES)17.
Thus far, the relationship between these anthropometric measures and the body composition of adults with 
type 1 diabetes at different stages of DN, expressed as the presence or absence of albuminuria, has not previously 
been investigated. Therefore, this study aimed to explore these relationships and seek to identify the anthropo-
metric measure to best estimate the visceral fat in this population with high cardiovascular risk.
Results
Data were available from a total of 246 men (30.5% with albuminuria) and 357 women (20.4% with albuminuria) 
(Table 1). In both men and women, individuals with albuminuria were older, had longer diabetes duration, higher 
systolic blood pressure and worse glycaemic control (Table 1).
Body composition according to the albuminuric stage. In men, BMI was no different between indi-
viduals with or without albuminuria (25.5 kg/m2 vs. 26.5 kg/m2, p = 0.08), albeit the two groups presented a dif-
ferent body composition. Men with albuminuria had greater BFM% (29.1% vs. 27.0%, p = 0.03), greater AFM% 
(3.0% vs. 2.4%, p = 0.02), and greater VFM% (1.5% vs. 1.0%, p = 0.001) compared with those without albuminu-
ria (Table 1). On the other hand, men with albuminuria had lower BLM% (67.3% vs. 69.2%, p < 0.04) and lower 
AppLM% (30.0% vs. 32.3%, p < 0.0001) than the normoalbuminuric men (Table 1).
In women, BMI was greater in the albuminuric group (27.2 kg/m2 vs. 25.4 kg/m2, p = 0.04) than in the nor-
moalbuminuric group. The BFM% (36.9% vs. 35.6%, p = 0.39) and the AFM% (3.0% vs. 2.7%, p = 0.16) were no 
different between women with or without albuminuria. However, we observed greater VFM% (0.9% vs. 0.5%, 
p = 0.001) in women with albuminuria (Table 1). Regarding the muscle mass, women with albuminuria had lower 
AppLM% (25.4% vs. 26.4%, p = 0.02) despite no difference in the BLM% (59.6% vs. 61.0%, p = 0.29) compared 
to the normoalbuminuric women (Table 1).
Body composition according to sex. In the whole cohort (independently of the presence or absence of 
albuminuria), men and women had comparable BMI (25.9 kg/m2 vs. 25.9 kg/m2, respectively, p = 0.87), despite 
different body composition (Table 2). Men had lower BFM% (27.91% vs. 35.98%, p < 0.0001), greater BLM% 
(68.41% vs. 60.73%, p < 0.0001), and greater AppLM% (31.49% vs. 26.27%, p < 0.001) than women (Table 2). 
Although the AFM% was comparable between men and women (2.63% vs. 2.71%, p = 0.54), the VFM% was 
greater in men (1.20% vs. 0.58%, p < 0.0001).
Associations between body composition and anthropometric measures. Measures of 
BFM%. WHtR, followed by the WC, was the anthropometric measure to best estimate the BFM% in men, 
independently of albuminuria (Table 3). In women, BMI followed by WC was the measure to best estimate the 
BFM%, also independently of albuminuria (Table 3). WHtR explained 60% of the BFM% variation in all men 
and 63% of the BFM% variation in all women. The BMI explained 47% of the BFM% variation in all men and 
70% of the BFM% variation in all women (Table 3). In our linear model, the WHtR cut-off of 0.5 corresponded 
to a BFM% of 25.0 in all men and a BFM% of 34.6 in all women (Table 4).
Measures of VFM%. WHtR, followed by the WC, was the anthropometric measure to best estimate the VFM% 
in men, while WC followed by WHtR was the best in women, independently of albuminuria (Fig. 1 and Table 3). 
The WHtR explained 68% of the VFM% variation in all men and 69% of the VFM% variation in all women 
(Table 3). WC explained 65% of the VFM% variation in all men and 71% of the VFM% variation in all women 
(Table 3). In our linear model, the WHtR cut-off of 0.5 corresponded to a VFM% of 1.1 in all men and a VFM% 
of 0.7 in all women (Table 4).
3
Vol.:(0123456789)
Scientific Reports |        (2020) 10:18575  | https://doi.org/10.1038/s41598-020-75667-5
www.nature.com/scientificreports/
Measures of BLM%. WHtR, followed by WC, was the anthropometric measure to best estimate BLM% in all 
men, while BMI followed by WC was the best measure in women, independently of albuminuria (Table  3). 
The WHtR explained 59% of the BLM% variation in all men and 62% of the BLM% variation in all women 
(Table 3). BMI explained only 46% of the BLM% variation in all men but 69% of the BLM% variation in all 
women (Table 3).
Table 1.  Body composition and clinical characteristics of men and women with and without albuminuria. 
HDL High density lypoprotein, HbA1c glycated hemoglobin. Data shown in medians (interquartile ranges), 
ABSI scaled A body shape index scaled by 100. P-Values were calculated separately for men and women by 
permutation analysis with 10,000 permutations.
Men Women
Normoalbuminuria Albuminuria p-value Normoalbuminuria Albuminuria p-value
N 171 75 284 73
Age (years) 44.3 (37.6, 52.9) 52.5 (41.3, 58.8) 0.0005 40.2 (32.5, 50.5) 49.8 (42.5, 56.1) < 0.0001
Diabetes duration 
(years) 22.4 (18.9, 34.7) 39.3 (30.3, 43.8) < 0.0001 24.0 (18.3, 34.7) 36.9 (24.8, 42.8) < 0.0001
Age of diabetes onset 
(years) 18.5 (13.1, 25.8) 12.6 (7.5, 17.8) 0.0004 12.7 (8.3, 20.6) 12.2 (7.0, 19.2) 0.67
Systolic blood pres-
sure (mmHg) 138 (129, 148) 145 (133, 160) 0.01 125 (116, 136) 135 (125, 150) 0.0002
Diastolic blood pres-
sure (mmHg) 78 (72, 84) 76 (70, 82) 0.42 75 (69, 81) 77 (70, 84) 0.19
HbA1c (mmol/mol) 61 (54, 69) 66 (58, 74) 0.0072 61 (54, 70) 68 (59, 80) 0.006
HbA1c (%) 7.7 (7.1, 8.5) 8.2 (7.5, 8.9) 0.0056 7.7 (7.1, 8.6) 8.4 (7.5, 9.5) 0.0051
Total cholesterol 
(mmol/L) 4.49 (3.96, 5.08) 4.27 (3.60, 4.90) 0.20 4.47 (4.06, 5.03) 4.56 (3.92, 5.00) 0.34
HDL cholesterol 
(mmol/L) 1.42 (1.17, 1.75) 1.42 (1.17, 1.76) 0.96 1.63 (1.39, 1.91) 1.72 (1.39, 1.98) 0.15
Triglycerides 
(mmol/L) 1.00 (0.77, 1.38) 1.12 (0.87, 1.84) 0.17 0.82 (0.64, 1.11) 1.03 (0.75, 1.48) 0.0002
Body mass index 
(kg/m2) 25.5 (24.0, 27.5) 26.5 (24.4, 29.0) 0.09 25.4 (22.7, 28.5) 27.2 (23.1, 31.0) 0.0477
ABSI scaled  (m(11/6)/
kg(2/3)) 7.85 (7.55, 8.23) 8.21 (7.9, 8.56) < 0.0001 7.37 (7.06, 7.75) 7.62 (7.34, 8.06) 0.0019
Height (cm) 181 (175, 185) 178 (173, 184) 0.12 166 (161, 170) 164 (160, 167) 0.29
Body weight (kg) 83.74 (75.56, 93.62) 83.84 (77.62, 93.24) 0.95 70.63 (62.19, 79.93) 72.41 (61.86, 84.86) 0.54
Waist circumference 
(cm) 93 (85, 99) 98 (89, 107) 0.01 81 (75, 91) 88 (78, 99) 0.0059
Hip circumference 
(cm) 99 (94, 103) 101 (95, 106) 0.19 99 (92, 107) 101 (93, 110) 0.44
Waist-hip ratio 0.93 (0.89, 0.98) 0.96 (0.93, 1.03) 0.0047 0.83 (0.79, 0.87) 0.85 (0.82, 0.90) 0.0068
Waist-height ratio 0.50 (0.48, 0.55) 0.55 (0.50, 0.59) 0.0002 0.49 (0.45, 0.55) 0.54 (0.48, 0.60) 0.0007
Body fat mass (kg) 21.87 (16.43, 27.97) 24.82 (21.06, 30.42) 0.0431 25.10 (18.77, 32.93) 28.72 (19.32, 35.25) 0.0398
Body fat mass per-
centage (%) 27.0 (21.5, 31.5) 29.1 (25.9, 33.3) 0.0331 35.6 (30.0, 41.2) 36.9 (32.0, 44.4) 0.39
Android fat mass (kg) 2.05 (1.28, 2.99) 2.64 (1.72, 3.48) 0.0090 1.86 (1.15, 2.70) 2.24 (1.13, 3.54) 0.07
Android fat mass 
percentage (%) 2.4 (1.6, 3.3) 3.0 (2.2, 3.9) 0.0295 2.7 (1.8, 3.5) 3.0 (1.9, 4.3) 0.16
Visceral fat mass (kg) 0.89 (0.46, 1.56) 1.30 (0.77, 2.05) 0.0070 0.39 (0.14, 0.80) 0.64 (0.26, 1.40) 0.0059
Visceral fat volume 
 (cm3)
939.31 (482.67, 
1652.63)
1376.19 (820.60, 
2175.97) 0.0044
410.84 (150.89, 
843.25)
681.71 (276.14, 
1480.26) 0.0078
Visceral fat mass 
percentage (%) 1.0 (0.5, 1.7) 1.5 (0.9, 2.4) 0.0013 0.5 (0.2, 1.0) 0.9 (0.4, 1.7) 0.0017
Visceral-Android 
fat ratio 0.45 (0.33, 0.56) 0.53 (0.43, 0.68) 0.0066 0.22 (0.12, 0.31) 0.30 (0.19, 0.45) 0.0005
Body lean mass (kg) 58.63 (53.90, 65.34) 56.31 (53.00, 61.30) 0.06 42.84 (39.75, 46.25) 42.72 (38.37, 48.90) 0.87
Body lean mass 
percentage (%) 69.2 (65.0, 74.6) 67.3 (63.3, 70.4) 0.0436 61.0 (55.6, 66.1) 59.6 (52.8, 64.5) 0.29
Appendicular lean 
mass (kg) 27.02 (24.21, 30.35) 25.20 (22.66, 28.24) 0.0083 18.74 (17.10, 20.36) 18.35 (16.35, 21.21) 0.43
Appendicular lean 
mass percentage (%) 32.3 (30.2, 34.2) 30.0 (28.0, 31.4)  < 0.0001 26.4 (24.6, 28.6) 25.4 (23.0, 27.2) 0.0268
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The BLM% was negatively associated with the VFM% in all men (beta − 5.58 [− 6.17, − 4.98], r2 = 0.59, 
p = 7.09 × 10–48) and in all women (beta − 7.88 [− 8.65, − 7.11],  r2 = 0.53, p = 1.23 × 10–60). The same association 
pattern was seen for both the normoalbuminuric and the albuminuric stage.
The BFM%, VFM% and BLM% associations with anthropometric measures according to the albuminuric 
stages are shown in Table 3.
WHR and ABSI showed a low association with the BFM%, VFM% and BLM%, independently of the albu-
minuric stage and sex (Table 3).
Misclassification of body fat. Considering the normal threshold of BFM% below 25 for men and below 
30 for women, the BMI misclassified 26.4% of the total cases (Table 5) by underestimating the body fat percent-
age in 20.6% of the cases and overestimating it in 5.8% (Table 5). The misclassification of BFM% by WC, WHR 
and WHtR were 22.6% (Table S1), 37.1% (Table S2) and 26.6% (Table S3), respectively.
Table 2.  Body composition and clinical characteristics between men and women. HDL High density 
lypoprotein, HbA1c glycated hemoglobin, CKD Chronic kidney disease. Data shown in medians (interquartile 
ranges), ABSI scaled A body shape index scaled by 100. p-values were calculated by permutation analysis with 
10,000 permutations.
Men Women p-value
N 246 357
Age (years) 46.62 (38.13, 55.8) 41.75 (33.26, 52.9) 0.0008
Diabetes duration (years) 26.56 (20.24, 39.53) 26.42 (19.39, 37.57) 0.96
Age of diabetes onset (years) 16.40 (10.90, 23.17) 12.48 (8.19, 20.19) < 0.0001
Systolic blood pressure (mmHg) 140.00 (129.00, 151.00) 127.00 (118.00, 140.00) < 0.0001
Diastolic blood pressure (mmHg) 77.50 (71.00, 84.00) 75.00 (69.00, 82.00) 0.0303
HbA1c (mmol/mol) 62.00 (55.00, 70.00) 63.00 (54.00, 72.00) 0.86
HbA1c (%) 7.82 (7.18, 8.56) 7.92 (7.09, 8.74) 0.86
Total cholesterol (mmol/L) 4.42 (3.89, 5.06) 4.48 (4.04, 5.02) 0.44
HDL cholesterol (mmol/L) 1.42 (1.17, 1.75) 1.63 (1.39, 1.92) < 0.0001
Triglycerides (mmol/L) 1.01 (0.78, 1.56) 0.84 (0.65, 1.21) < 0.0001
Body mass index (kg/m2) 25.9 (24.1, 28.4) 25.9 (22.8, 29.1) 0.87
ABSI scaled  (m(11/6)/kg(2/3)) 7.99 (7.65, 8.35) 7.42 (7.13, 7.8) < 0.0001
Height (cm) 180.00 (174.85, 185.00) 165.50 (161.00, 170.00) < 0.0001
Body weight (kg) 83.79 (77.13, 93.62) 70.98 (61.86, 80.70) < 0.0001
Waist circumference (cm) 94.00 (86.00, 102.00) 82.00 (76.00, 93.00) < 0.0001
Hip circumference (cm) 100.00 (95.00, 104.00) 100.00 (93.00, 108.00) 1.00
Waist-hip ratio 0.94 (0.89, 1.00) 0.83 (0.79, 0.87) < 0.0001
Waist-height ratio 0.51 (0.48, 0.57) 0.5 (0.46, 0.56) 0.0384
Body fat mass (kg) 22.91 (17.40, 28.48) 25.39 (18.79, 33.44) 0.0228
Body fat mass percentage (%) 27.91 (22.69, 32.16) 35.98 (30.24, 41.61) < 0.0001
Android fat mass (kg) 2.23 (1.36, 3.10) 1.90 (1.14, 2.94) 0.0143
Android fat mass percentage (%) 2.63 (1.86, 3.45) 2.71 (1.87, 3.63) 0.54
Visceral fat mass (kg) 1.00 (0.51, 1.73) 0.41 (0.16, 0.87) < 0.0001
Visceral fat volume  (cm3) 1063.96 (537.25, 1836.9) 438.67 (170.57, 926.56) < 0.0001
Visceral fat percentage (%) 1.20 (0.64, 1.93) 0.58 (0.26, 1.10) < 0.0001
Visceral-Android fat ratio 0.48 (0.37, 0.61) 0.23 (0.13, 0.33) < 0.0001
Body lean mass (kg) 57.9 (53.54, 64.52) 42.83 (39.66, 46.3) < 0.0001
Body lean mass percentage (%) 68.41 (64.19, 73.26) 60.73 (55.45, 66.04) < 0.0001
Appendicular lean mass (kg) 26.42 (23.64, 29.67) 18.62 (16.94, 20.44) < 0.0001
Appendicular lean mass percentage (%) 31.49 (29.41, 33.47) 26.27 (24.34, 28.43) < 0.0001
Normoalbuminuria (%) 69.51 79.55 0.0050
Microalbuminuria (%) 11.38 12.32 0.79
Macroalbuminuria (%) 19.11 8.12 0.0001
CKD stage 1 (%) 67.48 70.31 0.46
CKD stage 2 (%) 20.33 22.41 0.54
CKD stage 3 (%) 6.50 4.48 0.35
CKD stage 4 (%) 1.63 1.40 1.00
CKD stage 5 (%) 4.07 1.40 0.05
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Dependent 
variable
Independent 
variable
MEN WOMEN
beta value p value r2 zeta value beta value p value r2 zeta value
ALL
BFM% BMI 1.27 [1.10, 1.45] 5.75E−35 0.47 14.5689 1.30 [1.21, 1.39] 2.62E−94 0.70 28.6701
BFM% WAIST 0.46[0.41, 0.50] 3.73E−47 0.58 18.1633 0.49 [0.45, 0.53] 2.19 E−79 0.63 24.7941
BFM% WHR scaled 5.84 [4.78, 6.89] 1.01E−22 0.33 10.8811 3.58 [2.39, 4.76] 6.79E−09 0.09 5.9407
BFM% WHtR scaled 8.53 [7.65, 9.41] 4.19E−50 0.60 19.0456 7.94 [7.29, 8.58] 2.31E−77 0.63 24.2819
BFM% ABSI scaled 4.49 [3.53, 5.46] 2.24E−17 0.26 9.1591 1.98 [1.01, 2.96] 7.53E−05 0.04 4.006
VFM% BMI 0.17 [0.15, 0.19] 1.23E−36 0.53 15.0568 0.10 [0.09, 0.11] 3.26E−62 0.56 20.5214
VFM% WAIST 0.06 [0.05, 0.06] 5.16E−52 0.65 19.6216 0.05 [0.04, 0.05] 4.98E−95 0.71 28.8623
VFM% WHR scaled 0.91 [0.79, 1.03] 3.91E−35 0.51 14.6141 0.58 [0.49, 0.67] 6.93E−31 0.34 12.7462
VFM% WHtR scaled 1.15 [1.05, 1.26] 9.52E−57 0.68 21.0667 0.73 [0.67, 0.78] 5.66E−89 0.69 27.2620
VFM% ABSI scaled 0.63 [0.50, 0.75] 3.04E−20 0.36 10.097 0.41 [0.33, 0.48] 9.06E−23 0.27 10.539
BLM% BMI − 1.20 [− 1.36, −1.03] 8.21E−34 0.46 − 14.2243
− 1.22 [− 1.31, 
−1.14] 1.11E−91 0.69 − 27.9460
BLM% WAIST − 0.43 [− 0.48, −0.38] 1.08E−45 0.57 − 17.7289
− 0.46 [− 0.50, 
−0.43] 3.01E−73 0.63 − 24.4874
BLM% WHR scaled − 5.48 [− 6.49, −4.47] 4.39E−22 0.33 − 10.6808
− 3.38 [− 4.50, 
−2.26] 7.87E−08 0.09 − 5.9310
BLM% WHtR scaled − 8.02 [− 8.87, −7.17] 2.49E−48 0.59 − 18.5140
− 7.47 [− 8.09, 
−6.86] 1.10E−69 0.62 − 23.9328
BLM% ABSI scaled − 4.24 [− 5.16, −3.32] 4.47E−17 0.26 − 9.0586
− 1.91 [− 2.83, 
−0.99] 5.52E−05 0.05 − 4.0823
NORMOALBUMINURIA
BFM% BMI 1.29 [1.07, 1.51] 2.75E−23 0.45 11.6211 1.33 [1.22, 1.44] 3.62E−72 0.68 24.6341
BFM% WAIST 0.47 [0.40, 0.53] 1.37E−31 0.56 14.5603 0.51 [0.47, 0.56] 2.79E−59 0.61 20.9316
BFM% WHR scaled 5.50 [4.15, 6.86] 1.74E−13 0.28 8.0184 2.90 [1.51, 4.28] 5.11E−05 0.06 4.1141
BFM% WHtR scaled 9.01 [7.85, 10.17] 7.53E−34 0.59 15.3684 8.18 [7.40, 8.97] 7.16E−58 0.60 20.5365
BFM% ABSI scaled 4.25 [3.09, 5.41] 1.73E−11 0.24 7.219 1.38 [0.33, 2.43] 9.96E−03 0.02 2.5948
VFM% BMI 0.15 [0.13, 0.18] 1.55E−24 0.49 12.0640 0.09 [0.08, 0.10] 4.86E−49 0.55 18.0909
VFM% WAIST 0.06 [0.05, 0.06] 1.28E−36 0.63 16.3685 0.04 [0.04, 0.04] 8.21E−73 0.69 24.8252
VFM% WHR scaled 0.83 [0.69, 0.96] 4.22E−24 0.49 11.9099 0.44 [0.34, 0.53] 1.31E−17 0.25 9.1377
VFM% WHtR scaled 1.11 [0.99, 1.23] 1.62E−40 0.67 17.8027 0.65 [0.60, 0.70] 1.21E−69 0.68 23.8945
VFM% ABSI scaled 0.56 [0.43, 0.69] 8.10E−15 0.34 8.5327 0.30 [0.22, 0.37] 1.61E−14 0.21 8.1069
BLM% BMI − 1.21 [− 1.342 −1.00] 2.31E−22 0.44 − 11.2931
− 1.25 [− 1.35, 
−1.15] 9.06E−70 0.67 − 23.9314
BLM% WAIST − 0.44 [− 0.50, −0.38] 1.80E−30 0.55 − 14.1632
− 0.49 [− 0.53, 
−0.44] 2.18E−58 0.60 − 20.6812
BLM% WHR scaled − 5.17 [− 6.46, −3.87] 4.19E−13 0.27 − 7.8683
− 2.73 [− 4.05, 
−1.42] 5.68E−05 0.06 − 4.0881
BLM% WHtR scaled − 8.47 [− 9.59, −7.35] 1.32E−32 0.57 − 14.9230
− 7.71 [− 8.46, 
−6.96] 1.15E−56 0.59 − 20.1996
BLM% ABSI scaled − 4.02 [− 5.13, −2.91] 2.23E−11 0.24 − 7.1732
− 1.36 [− 2.35, 
−0.36] 7.62E−03 0.03 − 2.6878
ALBUMINURIA
BFM% BMI 1.19 [0.91, 1.46] 7.13E−13 0.51 8.7138 1.23 [1.06, 1.40] 1.06E−22 0.75 14.4528
BFM% WAIST 0.42 [0.34, 0.50] 9.42E−16 0.59 10.2710 0.45 [0.39, 0.52] 1.17E−21 0.73 13.8017
BFM% WHR scaled 6.42 [4.59, 8.25] 1.21E−09 0.40 6.9794 5.76 [3.31, 8.21] 1.32E−05 0.24 4.6882
BFM% WHtR scaled 7.60 [6.17, 9.03] 2.36E−16 0.61 10.6015 7.62 [6.49, 8.75] 4.90E−21 0.72 13.4210
BFM% ABSI scaled 4.23 [2.44, 6.01] 1.14E−05 0.24 4.7174 3.93 [1.74, 6.13] 6.41E−04 0.16 3.5746
VFM% BMI 0.19 [0.15, 0.23] 9.37E−14 0.60 9.1872 0.13 [0.10, 0.15] 3.69E−15 0.60 10.0194
VFM% WAIST 0.07 [0.05, 0.08] 7.43E−16 0.65 10.3277 0.05 [0.05, 0.06] 2.46E−22 0.75 14.2240
VFM% WHR scaled 1.07 [0.80, 1.34] 2.01E−11 0.54 7.9376 0.97 [0.74, 1.20] 2.49E−12 0.52 8.4698
VFM% WHtR scaled 1.19 [0.97, 1.41] 7.48E−17 0.67 10.8776 0.87 [0.73, 1.01] 5.88E−20 0.71 12.7699
VFM% ABSI scaled 0.63 [0.35, 0.91] 2.74E−05 0.32 4.4807 0.72 [0.50, 0.94] 6.42E−09 0.40 6.608
BLM% BMI − 1.12 [− 1.38, −0.86] 1.23E−12 0.51 − 8.5875
− 1.15 [− 1.31, 
−0.99] 1.75E−22 0.75 − 14.3175
BLM% WAIST − 0.40 [− 0.48, −0.32] 2.09E−15 0.59 − 10.0821
− 0.42 [− 0.48, 
−0.36] 2.06E−21 0.73 − 13.6507
BLM% WHR scaled − 6.03 [− 7.79, −4.27] 2.18E−09 0.39 − 6.8395
− 5.45 [− 7.76, 
−3.15] 1.15E−05 0.25 − 4.7251
Continued
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Dependent 
variable
Independent 
variable
MEN WOMEN
beta value p value r2 zeta value beta value p value r2 zeta value
BLM% WHtR scaled − 7.15 [− 8.53, −5.77] 8.14E−16 0.60 − 10.3058
− 7.16 [− 8.23, 
−6.09] 6.63E−21 0.72 − 13.3407
BLM% ABSI scaled − 3.94 [− 5.65, −2.23] 1.81E−05 0.23 − 4.593
− 3.68 [− 5.75, 
−1.61] 6.91E−04 0.16 − 3.5513
Table 3.  Associations between body composition and anthropometric measures according to the albuminuric 
stages. BMI body mass index (kg/m2), WAIST waist circumference (cm), WHR scaled waist-hip ratio*10, 
WHtR scaled waist-height ratio*10, ABSI scaled a body shape index scaled by standard deviation, BFM % 
body fat mass percentage, BLM % body lean mass percentage, VFM % visceral fat mass percentage, Beta linear 
regression coefficients adjusted for age, r2 coefficient of determination from the linear regression, the relevance 
ranking of each variable was based on the z statistics.
Table 4.  Percentage of total and visceral body fat related to BMI, WC and WHtR cut-offs according to the 
albuminuric stages. BMI body mass index (kg/m2), WC waist circumference (cm), WHtR waist-height ratio, 
BFM% body fat mass percentage, VFM% visceral fat mass percentage. WC was considered normal if < 94 cm 
for men and < 80 cm for women. WHtR was considered normal if < 0.5 for both sexes. BMI was considered 
normal if < 25 kg/m2, overweight if ≥ 25 and < 30 kg/m2 and obese if ≥ 30 kg/m2.
Sex BMI 25 BMI 30 WC (94/80) WHtR 0.5
BFM%
All
 Men 25.6 31.8 26.9 25.0
 Women 33.9 40.4 33.3 34.6
Normoalbuminuria
 Men 25.0 31.2 26.7 24.9
 Women 34.0 40.6 33.4 34.9
Albuminuria
 Men 27.2 33.0 27.4 25.4
 Women 33.9 40.0 32.7 33.5
VFM%
All
 Men 1.2 2.0 1.3 1.1
 Women 0.6 1.1 0.5 0.7
Normoalbuminuria
 Men 1.1 1.8 1.3 1.0
 Women 0.6 1.0 0.5 0.6
Albuminuria
 Men 1.5 2.3 1.5 1.1
 Women 0.8 1.5 0.6 0.7
Figure 1.  Associations between visceral fat and anthropometric measures in adults with type 1 diabetes 
according to sex.
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Discussion
In this study, we investigated for the first time the body composition of individuals with type 1 diabetes with 
and without albuminuria. We showed that individuals with albuminuria, regardless of sex, had greater visceral 
fat percentage and lower appendicular lean mass percentage, which is a dangerous combination regarding the 
risk of  CVD8,18,19. This finding is even more relevant if we consider that this population already has a high car-
diovascular risk because of diabetes and  DN1,3,20.
We showed that individuals with similar BMI have very different body composition, especially concerning the 
percentage of visceral fat and lean mass. This result emphasizes the importance of knowing the body composition 
instead of only BMI in a high cardiovascular risk population. The increase in body weight with a central distribu-
tion favours the accumulation of visceral fat that leads to an inflammatory state and insulin  resistance10, which 
has been associated with kidney  disease11,12,21. To make the situation worse, low lean  mass22 and kidney  disease23 
are also associated with muscle insulin resistance. Considering that this is a cross-sectional study, it is not pos-
sible to say if the visceral fat, which is linked to chronic inflammation and insulin resistance, is contributing to 
the development of albuminuria or the albuminuric stage is worsening the visceral fat and insulin resistance due 
to physical inactivity, inflammation, changes in the microbiome or other  factors21.
Most importantly, in this study, we found a strong association between VFM% and simple measures such 
as WHtR and WC, independently of the albuminuric stage and sex. We are not aware of any other study in 
individuals with type 1 diabetes that have previously assessed such relationships, especially looking at different 
stages of albuminuria. WHtR has been associated with central obesity and cardiovascular risk in the general 
population and in people with type 2  diabetes13–15. Furthermore, in a large prospective study including 109,536 
postmenopausal women, it has been linked to cardiovascular  events24. However, the relationship between WHtR 
and VFM% has never been described in individuals with type 1 diabetes with and without albuminuria. Given 
that DN increases cardiovascular mortality several-fold20,25 and that visceral fat is closely associated with  CVD8, 
18, our results regarding the association between WHtR and visceral fat are consistent with the literature which 
has shown the WHtR is a better screening tool than BMI for cardiometabolic risk  factors16. Therefore, this study 
brings up new important information regarding central obesity in individuals with type 1 diabetes, a subject that 
most of the time has been related to type 2 diabetes. In this respect, it is important to acknowledge that obesity 
is increasing among individuals with type 1 diabetes and at the same time, there has been an increase in the 
mortality rate starting from a normal range of  BMI1.
Another novel finding of this study was the negative association between BLM% and WHtR and WC, inde-
pendently of the albuminuric stage. Although BLM% was best estimated by WHtR in men and by BMI in women, 
the simple measurement of WC was the second-best for the estimation of BLM% in both sexes. A plausible expla-
nation for why WC and WHtR can estimate the percentage of body lean mass is the negative association between 
BLM% and VFM%. Although a recent publication showed that the fat-free mass was not associated with  CVD7, 
it does not exclude the relevance of our findings, since one has to take into consideration that the fat-free mass 
measured by bioimpedance includes not only the muscle mass and, in our study, we measured the body lean mass 
by DXA, which has better accuracy than the  bioimpedance5. From a clinical perspective, we found a simple and 
accessible tool to estimate the body lean mass in individuals with type 1 diabetes, independently of albuminuria.
Since low skeletal muscle mass is linked to  CVD19 and muscle wasting has been associated with premature 
death in individuals with end-stage renal  disease26 another important clinical finding was that, independently of 
sex, individuals with albuminuria have lower AppLM% compared to those without albuminuria, which might 
contribute to the increase in the cardiovascular risk of this high-risk population. Muscle wasting is not rare in 
individuals with end-stage renal  disease26,27 and although we did not include such individuals in our analyses, we 
showed that individuals with type 1 diabetes at the earlier stages of DN (micro and macroalbuminuria) already 
show a decrease in their BLM% compared to those with normoalbuminuria.
According to previous publications including individuals with obesity and/or type 2 diabetes, in the current 
study, the ABSI was positively associated with central obesity and negatively associated with body lean  mass28,29. 
However, it was inferior to the other anthropometric measures for the estimation of BFM%, VFM% and BLM% in 
our sample composed by Caucasian-Finnish individuals with type 1 diabetes. Since ABSI is a formula composed 
by WC adjusted for weight and height, the association between ABSI and body composition may vary depending 
on the characteristics of the studied population and on ethnicity.
In our study, BMI was not the anthropometric measure to best estimate VFM% in both sexes, and this inability 
of BMI to reflect the abdominal fat has been discussed  erlier4. It was not useful to estimate BFM% and BLM% in 
men either, although it was in women. The relationship between BMI and BFM% was studied previously in the 
general  population30 and the percentage of body fat mass related to the BMI was similar to our study. However, 
Table 5.  Misclassification of body fat percentage by BMI. The normal body fat percentage was considered: ≤ 25 
for men and ≤ 30 for women. DXA: Dual-energy X-Ray Absorptiometry. Percentages are based on the total 
number of 603 scans.
BMI < 25
(n)
BMI ≥ 25
(n)
TOTAL
(n)
Normal body fat percentage (n, %) 137 (22.7) 35 (5.8) 172 (28.5)
Excess body fat percentage (n, %) 124 (20.6) 307 (50.9) 431 (71.5)
Number (%) of DXAs 261 (43.3) 342 (56.7) 603 (100.00)
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the American  study30 did not investigate the associations between VFM%, BLM% with BMI, not either with 
WHtR and WC such as our study.
Furthermore, BMI misclassified BFM% in 26% of the total cases and underestimated it in 21% of them. 
Although the level of misclassification by BMI in our study is lower than in a previous  study31, it might be 
explained by the different methods used to assess the body composition. In the previous study, they used bioim-
pedance while we used DXA, which provides better  accuracy5. However, such as misclassification is clinically 
relevant, since individuals considered to have normal body weight by BMI might, in fact, have an excess of body 
fat and visceral fat, which are both closely associated with cardiovascular  mortality8,13,32,33. The misclassification 
by BMI is another possible explanation of why the mortality rate in individuals with type 1 diabetes starts to 
increase already from the normal range of  BMI1 Interestingly, the WC and WHtR misclassify the BFM% at least 
similarly to BMI, although they are in fact measures to estimate the central fat and not the total body fat. This 
finding is clinically important since a simple measure of WHtR or WC could not only better estimate visceral 
fat than BMI, but was able to classify obesity (BFM%) as well as BMI.
Another novelty of this study is to show, by our linear models, how much of the body fat mass and visceral fat 
mass percentages are related to the cut-offs of BMI, WC and WHtR. Interestingly, the BFM% and VFM% related 
to the BMI of 25 kg/m2 are similar to BFM% and VFM% related to the WHtR of 0.5. Therefore, our finding may 
provide a clue, why there is an increase in the mortality rate of this population starting from a BMI of 24.8 kg/
m2 1. These results may question whether the BMI of 25 kg/m2 is the best cut-off to define central obesity and 
cardiovascular risk in individuals with type 1 diabetes.
A limitation of this study is that we can not exclude confounding factors such as lifestyle and ethnicity. Since 
we studied a homogenous all-Caucasian Finnish population with type 1 diabetes and there are different thresh-
olds for waist circumference and BMI for different  ethnicities4,34, our results may not be applicable for all ethnici-
ties. Another limitation is its cross-sectional design; therefore, it is not possible to conclude any causality between 
the associations we found nor any prediction of CVD risk. However, these results motivate further prospective 
studies to investigate the impact of body composition on chronic diabetes complications in individuals with type 
1 diabetes. Another strength is its wide applicability to clinical practice since we here provide easily applicable 
tools to estimate the percentage of visceral fat and lean mass in a population with a high cardiovascular risk.
In conclusion, this study shows that simple measures such as WHtR and WC can estimate the VFM% in 
adults with type 1 diabetes independently of albuminuric stage and sex. Furthermore, it showed that individuals 
with type 1 diabetes and albuminuria, a population of high CVD risk, have greater VFM% and lower AppLM% 
compared to those with normoalbuminuria. From the clinical perspective, this study supports the routine moni-
toring of WHtR in adults with type 1 diabetes.
Methods
Study design and population. In this cross-sectional study, we explored the body composition and its 
relationship with anthropometric measures in individuals with type 1 diabetes with and without albuminuria. 
Adults with type 1 diabetes (n = 579) from the Finnish Diabetic Nephropathy (FinnDiane) Study cohort that had 
a DXA scan (n = 603) between August 2011 and June 2019 were included in this analysis. For 24 individuals, 
two scans were performed 5.3 ± 1.4 years apart as part of a regular follow-up visit. Sensitivity analysis including 
only the first scan (n = 579) for each individual led to the same conclusions (data not shown). Since 1997 the 
FinnDiane Study is recruiting and thoroughly characterizing individuals with type 1 diabetes 18 years or older 
at 93 centers across Finland. Type 1 diabetes is defined as age at onset of diabetes under 40 years and permanent 
insulin treatment initiated within a year from the diabetes diagnosis. The study protocol is designed according 
to the principles of the Declaration of Helsinki as revised in 2000 and was approved by the Ethics Committee of 
Helsinki and Uusimaa Hospital District. Written informed consents are obtained from each FinnDiane Study 
participant.
Diabetic nephropathy (DN) stage. Normoalbuminuria was defined as an urinary albumin excretion 
rate (UAER) < 20  µg/min or < 30  mg/24  h in at least two out of three urine samples. Microalbuminuria was 
defined as a UAER ≥ 20 and < 200 µg/min or ≥ 30 and < 300 mg/24 h and macroalbuminuria as a UAER ≥ 200 µg/
min or ≥ 300 mg/24 h. Individuals with micro- or macroalbuminuria were pooled together for analyses and will 
be referred throughout the paper as the albuminuric group. Individuals with end-stage renal disease (either on 
dialysis or have received a kidney transplant) were not included in this study.
Body composition and anthropometric measurements. Body composition was evaluated by DXA 
(GE Healthcare Lunar version 16, Wisconsin, USA) according to the manufacturer’s instructions and visceral fat 
was measured by  CoreScan35. A total body fat percentage below 25 was considered normal for men and below 30 
for  women30,31. The body fat mass percentage (BFM%), android fat mass percentage (AFM%), visceral fat mass 
percentage (VFM%), body lean mass percentage (BLM%), and appendicular lean mass percentage (AppLM%) 
were calculated by dividing the variable (grams) by total body weight (grams). Appendicular lean mass refers to 
the lean mass of both legs and arms.
BMI was calculated as total body weight (kilograms) divided by the square of the height (meters)36 and indi-
viduals were stratified by their BMI as normal weight (19–24.9 kg/m2), overweight (25–29.9 kg/m2) and obese 
(≥ 30 kg/m2)36. WC was measured in centimeters by a stretch‐resistant tape at the horizontal plane midway in 
the distance of superior iliac crest and the lower margin of the last  rib34. The WC was considered normal if it 
was below 94 cm for men and below 80 cm for  women37. The hip circumference was measured with the same 
tape around the widest part over the great trochanters and WHR was calculated by dividing the WC by the hip 
 circumference34. A WHR below 0.9 for men and below 0.85 for women were considered  normal34. The WHtR 
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was calculated by dividing the WC by the height and values below 0.5 were considered normal for both men and 
 women13. ABSI was calculated by the formula WC/(BMI2/3height½)17.
Statistical analyses. For the analyses, we split the cohort into men and women and further distinguished 
between individuals with and without albuminuria.
Data on categorical variables are presented as frequencies, while continuous variables as medians (interquar-
tile ranges, IQR). Between-group comparisons were conducted via permutation tests with 10,000 permutations. 
To compare the anthropometric measures for their capacity to estimate body composition, we performed linear 
regression analyses adjusted for age with the measurements of body composition as the dependent variables and 
anthropometric measures as the independent variables. The regressions’  R2 values were used to describe the 
proportion of the variance of a body composition measure that is explained by an anthropometric measure. 
The relevance ranking of each variable was based on the z statistics allowing comparisons across risk factors 
independently of their measurement  units38. WHR and WHtR were scaled by a factor of 10. All analyses were 
performed in  R39.
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